BioSurface Technology Inc. announced Wednesday that itcompleted an initial public offering of 2.5 million shares ofcommon stock at $12 a share.
The Cambridge, Mass., company (NASDAQ:BSRF) granted itsunderwriters, Hambrecht & Quist Inc. and Cowen & Co., anoption to purchase an additional 375,000 shares of commonstock to cover overallotments.
BioSurface uses proprietary cell culture technology to grownormal human cells and form biologically active tissue in vitro.
(c) 1997 American Health Consultants. All rights reserved.